Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Income: 2009-2024

Historic Net Income for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$573.9 million.

  • Cytokinetics' Net Income fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • Cytokinetics' Net Income amounted to -$573.9 million in FY2024, which was down 9.43% from -$524.5 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Net Income registered a high of -$109.9 million during FY2020, and its lowest value of -$573.9 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$524.5 million (2023), whereas its average is -$480.7 million.
  • Data for Cytokinetics' Net Income shows a maximum YoY slumped of 84.48% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Cytokinetics' Net Income stood at -$109.9 million in 2020, then plummeted by 84.48% to -$202.8 million in 2021, then plummeted by 69.48% to -$343.6 million in 2022, then plummeted by 52.64% to -$524.5 million in 2023, then decreased by 9.43% to -$573.9 million in 2024.